New Haven, Connecticut
Colorectal cancer clinical trials in New Haven, CT
35 colorectal cancer studies are recruiting participants at sites in New Haven as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
New Haven at a glance
- 35 studies are recruiting at a site in New Haven.
- By phase: Phase 1 (10), Phase 1/2 (10), Phase 2 (3), Phase 2/3 (1), Phase 3 (6), No phase (5). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (27), university, hospital or other (7), government (1).
- Most recent update to one of these records: November 16, 2026.
Studies recruiting in New Haven
Basic details from each study's public record (the 30 most recently updated of 35). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study site
- Yale University School of Medicine
- Registry record
- NCT06324357 · updated
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- Smilow Cancer Hospital - Yale New Haven Health · Smilow Cancer Hospital Phase 1 Unit · Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP
- Registry record
- NCT04557449 · updated
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- Yale Cancer Center
- Registry record
- NCT07503808 · updated
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Yale Cancer Center
- Registry record
- NCT04929223 · updated
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT07228832 · updated
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- No phase
- Ages 45 to 70
- All sexes
- Sponsor
- NRG Oncology
- Study site
- Yale University
- Registry record
- NCT05080673 · updated
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- NRG Oncology
- Study sites
- Smilow Cancer Center/Yale-New Haven Hospital · Yale University
- Registry record
- NCT05174169 · updated
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Yale University School Of Medicine
- Registry record
- NCT06662786 · updated
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Immunome, Inc.
- Study site
- Yale Cancer Center
- Registry record
- NCT07578571 · updated
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- AbbVie
- Study site
- Yale New Haven Hospital /ID# 270565
- Registry record
- NCT06820463 · updated
The Cancer of the Pancreas Screening-5 CAPS5)Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Johns Hopkins University
- Study site
- Yale University
- Registry record
- NCT02000089 · updated
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- AbbVie
- Study site
- Yale University School of Medicine /ID# 279373
- Registry record
- NCT07525206 · updated
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Criterium, Inc.
- Study site
- Yale University
- Registry record
- NCT06992258 · updated
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Institut de Recherches Internationales Servier
- Study site
- Yale University School of Medicine - Yale Cancer Center
- Registry record
- NCT05786924 · updated
FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Parabilis Medicines, Inc.
- Study site
- Yale University School of Medicine
- Registry record
- NCT05919264 · updated
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- PMV Pharmaceuticals, Inc
- Study site
- Yale Cancer Center
- Registry record
- NCT04585750 · updated
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- Exelixis Clinical Site #62
- Registry record
- NCT05176483 · updated
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Yale-New Haven Hospital-Yale Cancer Center
- Registry record
- NCT06445062 · updated
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Yale Cancer Center
- Registry record
- NCT07349537 · updated
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- EvolveImmune United, Inc
- Study site
- Yale University Cancer Center
- Registry record
- NCT07217171 · updated
Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- Medtronic - MITG
- Study site
- Yale University
- Registry record
- NCT07351071 · updated
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Xencor, Inc.
- Study site
- Xencor Investigative Site
- Registry record
- NCT05433142 · updated
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Yale University
- Registry record
- NCT05691491 · updated
A Study of ASP1002 in Adults for Treatment of Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- Yale University Cancer Center
- Registry record
- NCT05719558 · updated
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis
- No phase
- Ages 18 to 81
- All sexes
- Sponsor
- Yale University
- Study site
- Yale New Haven Hospital
- Registry record
- NCT07291180 · updated
Colorectal Cancer Screening Outreach
- No phase
- Ages 45 to 75
- All sexes
- Sponsor
- Yale University
- Study site
- Cornell Scott Hill Health
- Registry record
- NCT07345676 · updated
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Alentis Therapeutics AG
- Study site
- Yale Comprehensive Cancer Center
- Registry record
- NCT07169734 · updated
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- BioNTech SE
- Study site
- Yale University
- Registry record
- NCT07079631 · updated
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Smilow Cancer Hospital (Yale University)
- Registry record
- NCT06040541 · updated
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Study site
- Yale University
- Registry record
- NCT06917079 · updated
Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in New Haven, CT on ClinicalTrials.gov.
Ask about studies near New Haven
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections